Sue Hughes is a medical journalist with over 20 years of experience. She currently writes for Medscape and MDEdge, covering a wide range of topics in cardiology and neurology. Her articles provide valuable insights into the latest research, treatment options, and developments in the medical field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Sue Hughes' articles predominantly focus on healthcare and pharmaceuticals, particularly in the realms of migraine treatment, CGRP inhibitors, hypertension, and cardiovascular risk. Her coverage mainly cites data to support her insights.
If reaching out to Sue with a pitch or as a source, consider providing scientifically backed information on new developments in these fields or offering access to experts who can provide detailed analysis based on verifiable data. This could involve sharing new clinical trial results or evidence-based research findings related to the topics she covers.
Since Sue primarily focuses on citing data in her articles, it would be beneficial to emphasize any statistics or scientific studies that back up your pitches when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sue Hughes
The full results of the ANNEXA-I trial have continued to show mixed effects of the factor Xa inhibitor reversal agent, andexanet (Andexxa/Ondexxya, AstraZeneca), in
The incidence of antidepressant discontinuation symptoms appears to be much lower than was previously thought, results from a new meta-analysis of studies assessing this issue showed.
The market for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to lower cholesterol is taking off with several new drugs being
Early intensive uptitration of neurohormonal blockade therapy in patients with acute heart failure improves congestion and reduces longer term negative outcomes, a new analysis of the STRONG-HF trial suggested.
The market for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to lower cholesterol is taking off with several new drugs being introduced or nearing the market, which will increase competition and enable more patients to reach low-density lipoprotein (LDL) goals, experts said.
Receipt of a newer recombinant version of a shingles vaccine is associated with a significant delay in dementia diagnosis in older adults, a new study suggests.
LONDON — Simplified and more aggressive targets are among the significant changes to the updated hypertension guidelines released by the European Society of Cardiology.
The long-debated question of whether mineralocorticoid receptor antagonists are effective for heart failure with mildly reduced or preserved ejection fraction has been answered in a new trial.
LONDON — Vutrisiran , a gene-silencing drug, led to impressive reductions in all-cause death and recurrent cardiovascular events in patients with
May 6, 2020 | Rheumatology News Four more studies of the relationship of angiotensin-converting enzyme (ACE) inhibitors and
(833) 317-6278 
